Drugs / EGFRt/19-28z/IL-12 CAR T-lymphocytes
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06343376 | Nov 2024 → Jan 2025 | Richter transformation, chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, high grade B-cell lymphoma +1 | Roswell Park Cancer Institute | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EGFRt/19-28z/IL-12 CAR T-lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06343376 ↗ |
| Modality | Cell therapy | “Chimeric Antigen Receptor (CAR) T-cell Therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will...” NCT06343376 ↗ |
| Route | Intravenous | “intravenously (IV)” NCT06343376 ↗ |
| Target | CD19 | “CD19-targeted” NCT06343376 ↗ |